181 related articles for article (PubMed ID: 22687453)
1. Targeting the PI3K/AKT/mTOR signaling axis in children with hematologic malignancies.
Barrett D; Brown VI; Grupp SA; Teachey DT
Paediatr Drugs; 2012 Oct; 14(5):299-316. PubMed ID: 22845486
[TBL] [Abstract][Full Text] [Related]
2. Status of PI3K/Akt/mTOR pathway inhibitors in lymphoma.
Westin JR
Clin Lymphoma Myeloma Leuk; 2014 Oct; 14(5):335-42. PubMed ID: 24650973
[TBL] [Abstract][Full Text] [Related]
3. Targeting the PI3K/Akt/mTOR pathway--beyond rapalogs.
Markman B; Dienstmann R; Tabernero J
Oncotarget; 2010 Nov; 1(7):530-543. PubMed ID: 21317449
[TBL] [Abstract][Full Text] [Related]
4. Differentiating mTOR inhibitors in renal cell carcinoma.
Pal SK; Quinn DI
Cancer Treat Rev; 2013 Nov; 39(7):709-19. PubMed ID: 23433636
[TBL] [Abstract][Full Text] [Related]
5. Combined treatment with crizotinib and temsirolimus is an effective strategy in mantle cell lymphoma and can overcome acquired resistance to temsirolimus.
Moosburner M; Alibegovic L; Hasselmann K; Gaiderov A; Hildebrand J; Philippou-Massier J; Blum H; Fischer L; Dreyling M; Silkenstedt E
Hematol Oncol; 2023 Dec; 41(5):858-868. PubMed ID: 37300279
[TBL] [Abstract][Full Text] [Related]
6. Novel targeted therapies for mantle cell lymphoma.
Alinari L; Christian B; Baiocchi RA
Oncotarget; 2012 Feb; 3(2):203-11. PubMed ID: 22361516
[TBL] [Abstract][Full Text] [Related]
7. New molecular targets in mantle cell lymphoma.
Parekh S; Weniger MA; Wiestner A
Semin Cancer Biol; 2011 Nov; 21(5):335-46. PubMed ID: 21945517
[TBL] [Abstract][Full Text] [Related]
8. The mTOR Signaling Pathway and mTOR Inhibitors in Cancer: Next-generation Inhibitors and Approaches.
Ihlamur M; Akgul B; Zengin Y; Korkut ŞV; Kelleci K; Abamor EŞ
Curr Mol Med; 2024; 24(4):478-494. PubMed ID: 37165594
[TBL] [Abstract][Full Text] [Related]
9. Targeting mTOR for the treatment of B cell malignancies.
Lee JS; Vo TT; Fruman DA
Br J Clin Pharmacol; 2016 Nov; 82(5):1213-1228. PubMed ID: 26805380
[TBL] [Abstract][Full Text] [Related]
10. The Role of mTOR in B Cell Lymphoid Malignancies: Biologic and Therapeutic Aspects.
Karatrasoglou EA; Dimou M; Piperidou A; Lakiotaki E; Korkolopoulou P; Vassilakopoulos TP
Int J Mol Sci; 2023 Sep; 24(18):. PubMed ID: 37762410
[TBL] [Abstract][Full Text] [Related]
11. PI3K/AKT/mTOR Signaling Pathway in HPV-Driven Head and Neck Carcinogenesis: Therapeutic Implications.
Aguayo F; Perez-Dominguez F; Osorio JC; Oliva C; Calaf GM
Biology (Basel); 2023 Apr; 12(5):. PubMed ID: 37237486
[TBL] [Abstract][Full Text] [Related]
12. Genetic heterogeneity and prognostic impact of recurrent ANK2 and TP53 mutations in mantle cell lymphoma: a multi-centre cohort study.
Jeong S; Park YJ; Yun W; Lee ST; Choi JR; Suh C; Jo JC; Cha HJ; Jeong JY; Chang H; Cha YJ; Kim H; Park MJ; Song W; Cho EH; Jeong EG; Lee J; Park Y; Lee YS; Kim DJ; Lee HS
Sci Rep; 2020 Aug; 10(1):13359. PubMed ID: 32770099
[TBL] [Abstract][Full Text] [Related]
13. Conditional Knockout of Raptor/mTORC1 Results in Dentin Malformation.
Xie F; Dai Q; Liu X; Wang J
Front Physiol; 2019; 10():250. PubMed ID: 30984011
[TBL] [Abstract][Full Text] [Related]
14. mTOR activity in AIDS-related diffuse large B-cell lymphoma.
Browne SH; Diaz-Perez JA; Preziosi M; King CC; Jones GA; Jain S; Sun X; Reid EG; VandenBerg S; Wang HY
PLoS One; 2017; 12(2):e0170771. PubMed ID: 28192480
[TBL] [Abstract][Full Text] [Related]
15. Mantle cell lymphoma in the era of precision medicine-diagnosis, biomarkers and therapeutic agents.
Inamdar AA; Goy A; Ayoub NM; Attia C; Oton L; Taruvai V; Costales M; Lin YT; Pecora A; Suh KS
Oncotarget; 2016 Jul; 7(30):48692-48731. PubMed ID: 27119356
[TBL] [Abstract][Full Text] [Related]
16. Targeting mTOR in mantle cell lymphoma: current and future directions.
Smith SM
Best Pract Res Clin Haematol; 2012 Jun; 25(2):175-83. PubMed ID: 22687453
[TBL] [Abstract][Full Text] [Related]
17. Counteracting autophagy overcomes resistance to everolimus in mantle cell lymphoma.
Rosich L; Xargay-Torrent S; López-Guerra M; Campo E; Colomer D; Roué G
Clin Cancer Res; 2012 Oct; 18(19):5278-89. PubMed ID: 22879389
[TBL] [Abstract][Full Text] [Related]
18. [Antihormonal therapy in breast cancer and mTOR inhibitors].
Heudel PÉ; Tredan O; Ray-Coquard I; Treilleux I; Guastalla JP; Bachelot T
Bull Cancer; 2011 Dec; 98(12):1431-7. PubMed ID: 22133994
[TBL] [Abstract][Full Text] [Related]
19. New inhibitors of the mammalian target of rapamycin signaling pathway for cancer.
Albert S; Serova M; Dreyer C; Sablin MP; Faivre S; Raymond E
Expert Opin Investig Drugs; 2010 Aug; 19(8):919-30. PubMed ID: 20569080
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
